Incidence of tacrolimus-induced gingival overgrowth in the absence of calcium channel blockers: a short-term study.
OBJECTIVE
The aim of this study was to determine the incidence and severity of gingival overgrowth (GO) induced by tacrolimus (Tcr) compared with ciclosporin A (CiA) in the absence of calcium channel blockers (CCB) in renal transplant recipients.


METHODS
Forty patients (20 Tcr and 20 CiA) were evaluated before and 30 and 90 days after kidney transplantation. Demographic (age, gender) and periodontal parameters were recorded for all patients. Patients taking CCB at any time during the study were excluded from the investigation.


RESULTS
The mean GO score was significantly lower (p=0.014) in the Tcr group (6.4%) compared with the CiA group (17.9%) after 90 days of immunosuppressive therapy. At 90 days post-transplant, clinically significant GO was observed in four patients of the CiA group and in two of the Tcr group. This difference was not statistically significant (0.66).


CONCLUSIONS
No significant difference in the incidence of clinically significant GO was observed between the CiA and Tcr groups up to 90 days of immunosuppressive therapy.
Sekiguchi
Ricardo Takiy
RT
Department of Stomatology, Division of Periodontics, School of Dentistry, University of São Paulo, São Paulo, Brazil. takiy@usp.br
Paixão
Caroline Gomes
CG
Saraiva
Luciana
L
Romito
Giuseppe Alexandre
GA
Pannuti
Cláudio Mendes
CM
Lotufo
Roberto Fraga Moreira
RF
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002121:Calcium Channel Blockers; D016572:Cyclosporine / Q000009:adverse effects; D003774:Dental Plaque Index; D005260:Female; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000145:classification; D019214:Gingival Overgrowth / Q000139:chemically induced*; D005889:Gingival Recession / Q000145:classification; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000145:classification; D016559:Tacrolimus / Q000009:adverse effects*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000890:Anti-Infective Agents; D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D016572:Cyclosporine; D001379:Azathioprine; D016559:Tacrolimus